- Home
- AIRT vs GUTS Comparison
AIRT vs GUTS Comparison
Compare AIRT & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- GUTS
- Stock Information
- Founded
- AIRT 1980
- GUTS 2010
- Country
- AIRT United States
- GUTS United States
- Employees
- AIRT N/A
- GUTS N/A
- Industry
- AIRT Air Freight/Delivery Services
- GUTS
- Sector
- AIRT Consumer Discretionary
- GUTS
- Exchange
- AIRT Nasdaq
- GUTS NYSE
- Market Cap
- AIRT 53.2M
- GUTS 58.8M
- IPO Year
- AIRT N/A
- GUTS 2024
- Fundamental
- Price
- AIRT $21.13
- GUTS $1.64
- Analyst Decision
- AIRT
- GUTS Buy
- Analyst Count
- AIRT 0
- GUTS 1
- Target Price
- AIRT N/A
- GUTS $10.00
- AVG Volume (30 Days)
- AIRT 2.7K
- GUTS 939.7K
- Earning Date
- AIRT 06-27-2025
- GUTS 08-13-2025
- Dividend Yield
- AIRT N/A
- GUTS N/A
- EPS Growth
- AIRT N/A
- GUTS N/A
- EPS
- AIRT N/A
- GUTS N/A
- Revenue
- AIRT $291,850,000.00
- GUTS $60,000.00
- Revenue This Year
- AIRT N/A
- GUTS N/A
- Revenue Next Year
- AIRT N/A
- GUTS N/A
- P/E Ratio
- AIRT N/A
- GUTS N/A
- Revenue Growth
- AIRT 1.75
- GUTS N/A
- 52 Week Low
- AIRT $14.56
- GUTS $0.87
- 52 Week High
- AIRT $30.60
- GUTS $4.92
- Technical
- Relative Strength Index (RSI)
- AIRT 54.46
- GUTS 44.51
- Support Level
- AIRT $18.86
- GUTS $1.54
- Resistance Level
- AIRT $22.50
- GUTS $1.82
- Average True Range (ATR)
- AIRT 1.12
- GUTS 0.17
- MACD
- AIRT -0.05
- GUTS -0.06
- Stochastic Oscillator
- AIRT 47.07
- GUTS 13.12
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.